Study summary · research use only
P-21 Activated Kinases in Liver Disorders
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review discusses p21 Activated Kinases (PAKs), serine threonine kinases involved in cell growth, survival, cytoskeletal organization, migration, and morphology, in the context of liver disorders including liver cancer, hepatic ischemia-reperfusion injury, hepatitis, and liver fibrosis. The authors describe PAK activation as associated with liver cancer growth and metastasis and with reduced radiotherapy and chemotherapy sensitivity, and summarize PAK involvement in hepatitis, fibrosis, and ischemia-reperfusion injury. The review summarizes available studies on PAK mechanisms in liver disorders and discusses potential therapeutic application of PAK inhibitors as an overview of current progress and perspectives.
Abstract
The p21 Activated Kinases (PAKs) are serine threonine kinases and play important roles in many biological processes, including cell growth, survival, cytoskeletal organization, migration, and morphology. Recently, PAKs have emerged in the process of liver disorders, including liver cancer, hepatic ischemia-reperfusion injury, hepatitis, and liver fibrosis, owing to their effects in multiple signaling pathways in various cell types. Activation of PAKs promotes liver cancer growth and metastasis and contributes to the resistance of liver cancer to radiotherapy and chemotherapy, leading to poor survival of patients. PAKs also play important roles in the development and progression of hepatitis and other pathological processes of the liver such as fibrosis and ischemia-reperfusion injury. In this review, we have summarized the currently available studies about the role of PAKs in liver disorders and the mechanisms involved, and further explored the potential therapeutic application of PAK inhibitors in liver disorders, with the aim to provide a comprehensive overview on current progress and perspectives of PAKs in liver disorders.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.